糖尿病视网膜病变中Rho激酶的治疗潜力

Rho激酶最初被认为是G蛋白Rho的效应蛋白。Rho激酶参与了各种疾病，如癌症和心血管疾病，并且Rho激酶抑制剂已经在临床应用于脑血管痉挛和青光眼的相关治疗。糖尿病视网膜病变（diabetic retinopathy，DR）是糖尿病常见的并发症之一，也是导致视力丧失的主要原因。而抗VEGF治疗由于其很好的疗效最近被广泛用于DR的治疗，但相关的风险和并发症也得到广泛关注。在病理性糖尿病视网膜条件下，Rho激酶的重要性也得到阐明，使得其成为具有吸引力的一个潜在的治疗靶点。Rho激酶是参与血管生成和通透性以及各种疾病如炎症和神经变性的发病机制之一。这使得Rho激酶抑制剂成为DR的新的分子靶向药物。本文对Rho激酶作用机制及其在DR治疗中的应用做简要综述。

Therapeutic potential of Rho kinase in diabetic retinopathy

Rho-associated kinase is originally identified as an effector protein of the G protein Rho，which involves in various diseases，particularly in cancer and cardiovascular disease.Rho kinase inhibitors have already been applied clinically for cerebral vasospasm and glaucoma.Diabetic retinopathy （DR） is a common complication of diabetes which is the leading cause of visual loss.While anti-VEGF therapy has recently been widely used for DR patients due to its efficacy，but great attention has been drawn to the related risk and complications.The importance of Rho kinase in pathological vitreoretinal conditions has also been elucidated and is attracting attention as a potential therapeutic target.Rho kinase is involved in angiogenesis and hyperpermeability and also in the pathogenesis of various pathologies such as inflammation and neural degeneration，which has been expected that Rho kinase inhibitors will become a new molecular target drug for DR.This review summarizes the mechanism of Rho kinase action and its application in the treatment of DR.